A Comprehensive Review on Dyslipidemia and Obesity: Pathophysiology, Clinical Implications and Management Approaches

                             Edwin Dias^1,2 and Arunanjali A³*

1 HOD and Professor, Department of Paediatrics, Srinivas Institute of Medical Sciences and Research    

   Centre, Mangalore, Karnataka, India

2 Adjunct Professor, Srinivas University, Director of Research and Publication, India      

3 Final Year Pharm.D, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka, India

*Correspondence: dr.arunanjali@gmail.com;

DOI: https://doi.org/10.71431/IJRPAS.2025.41203

INTRODUCTION

Obesity and dyslipidemia are among the most prevalent modifiable risk factors for cardiovascular disease (CVD), representing a formidable global public health challenge. Obesity, defined as excessive accumulation of body fat that poses a health risk, contributes directly to dyslipidemia through multiple metabolic mechanisms and indirectly via its association with insulin resistance, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD).[1,2]

Over the past four decades, global obesity rates have tripled. According to the World Obesity Federation, nearly 2.5 billion adults are overweight, and about 890 million meet criteria for obesity.[3] Concomitantly, dyslipidemia manifested as elevated LDL cholesterol, hypertriglyceridemia or low HDL cholesterol is observed in nearly 60% of obese adults, depending on region and diagnostic criteria. [4]

The interplay between these disorders amplifies the risk of atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, hypertension, NAFLD and chronic kidney disease.[5] Both are largely preventable and treatable, yet their global control remains suboptimal due to urbanization, sedentary lifestyles, high-calorie diets, and limited awareness. [6]

The World Health Organization (WHO) and international guidelines underscore that early identification and aggressive management of dyslipidemia and obesity are essential to reducing cardiovascular events and improving longevity. [7]

EPIDEMIOLOGY

Global Trends

The prevalence of obesity has increased steadily in both developed and developing nations. Between 1980 and 2020, global obesity nearly tripled. By 2025, projections indicate that one in five adults will be obese if current trends continue.[8] Southeast Asia, the Middle East, and North America represent the highest growth regions, with female obesity rates exceeding 40% in some nations. [9]

Burden of Dyslipidemia

Dyslipidemia affects roughly 39% of the global population, with regional variations influenced by diet, genetics and socioeconomic status.[10] The Global Burden of Disease study attributes nearly 4.4 million deaths annuallyto high LDL-C levels, making it one of the top three metabolic risk factors for premature death. [11]

The Obesity–Dyslipidemia Nexus

Epidemiological surveys, such as NHANES and INTERHEART, demonstrate a near-linear relationship between BMI and plasma triglycerides and an inverse relationship with HDL-C. [12] Visceral adiposity is particularly associated with atherogenic dyslipidemia characterized by hypertriglyceridemia, small dense LDL, and low HDL-C — a pattern often referred to as atherogenic dyslipidemia of obesity. [13]

Economic and Public Health Implications

The combined costs of obesity-related cardiovascular and metabolic diseases exceed $2 trillion annually, accounting for about 3% of global GDP. [14] Healthcare systems are increasingly burdened by the need for chronic lipid-lowering therapy, management of diabetes and hypertension and treatment of related complications. Public health interventions focused on dietary reform, physical activity and early screening have shown substantial cost-effectiveness in multiple models. [15]

CLASSIFICATION AND PHENOTYPES

·         Obesity is commonly categorized by body mass index (BMI):

·         Normal weight: 18.5–24.9 kg/m²

·         Overweight: 25–29.9 kg/m²

·         Obesity (Class I): 30–34.9 kg/m²

·         Obesity (Class II): 35–39.9 kg/m²

·         Obesity (Class III, severe): ≥40 kg/m²

·         Ethnic-specific cutoffs (e.g., ≥25 kg/m² for Asian populations) better reflect risk in certain groups. [16]

Visceral vs Subcutaneous Obesity

Visceral adiposity, reflected by waist circumference (>90 cm in men, >80 cm in women in Asian populations), is more closely linked to insulin resistance and dyslipidemia than subcutaneous fat. [17]

Dyslipidemia Classification

·         According to NCEP-ATP III and ESC/EAS guidelines:

·         Isolated hypercholesterolemia: elevated LDL-C

·         Isolated hypertriglyceridemia: TG >150 mg/dL

·         Mixed dyslipidemia: elevated TG and LDL-C with low HDL-C

·         Atherogenic Dyslipidemia :This phenotype is hallmarked by:

Ø  TG >150 mg/dL

Ø  HDL-C <40 mg/dL (men), <50 mg/dL (women)

Ø  Increased small dense LDL particles

It strongly correlates with insulin resistance and abdominal obesity, forming the lipid component of the metabolic syndrome. [18]

PATHOPHYSIOLOGY

Insulin Resistance and Lipid Metabolism

Insulin resistance is the fundamental link between obesity and dyslipidemia. In a healthy state, insulin suppresses hepatic VLDL synthesis and stimulates lipoprotein lipase (LPL) activity in adipose tissue. However, in obesity, these processes are dysregulated:

Increased hepatic VLDL production: Excess free fatty acid flux from adipose tissue enhances hepatic triglyceride synthesis.

Reduced LPL activity: Impairs TG clearance from circulation, elevating plasma TG levels.

Altered apolipoprotein regulation: Elevated apoC-III inhibits TG hydrolysis, while apoB overproduction accelerates VLDL secretion. [19]

Adipose Tissue Dysfunction

Obese adipose tissue is metabolically active and secretes numerous adipokines and cytokines. The adipocyte hypertrophy leads to hypoxia, macrophage infiltration, and chronic low-grade inflammation.
Key molecules include:

TNF-α and IL-6 → promote hepatic lipogenesis and inhibit LPL.

Leptin → increases with fat mass but leptin resistance blunts its effect on lipid oxidation.

Adiponectin → declines in obesity; its deficiency contributes to insulin resistance and decreased fatty acid oxidation. [20]

Hepatic Lipid Overproduction

Non-alcoholic fatty liver disease (NAFLD), present in up to 70% of obese individuals, accelerates hepatic TG synthesis and VLDL secretion. Hepatic steatosis amplifies dyslipidemia through increased de novo lipogenesis and impaired cholesterol efflux. [21]

Formation of Small Dense LDL (sdLDL)

High VLDL levels promote lipid exchange with LDL particles via cholesteryl ester transfer protein (CETP). Hepatic lipase then hydrolyzes TG-rich LDL to form small dense LDL, which are highly atherogenic they penetrate the arterial wall easily and are more prone to oxidation. [22]

Impaired HDL Metabolism

In obesity, increased TG transfer to HDL and accelerated catabolism reduce HDL-C concentration and compromise reverse cholesterol transport, further promoting atherosclerosis. [23]

Genetic and Epigenetic Modifiers

Polymorphisms in genes regulating lipid metabolism (APOE, CETP, PCSK9, LDLR and LPL) modulate susceptibility to dyslipidemia in obesity. Epigenetic alterations driven by high-fat diets (DNA methylation of PPARγ and adiponectin genes) also contribute to metabolic inflexibility. [24]

MANAGEMENT OF OBESITY-RELATED DYSLIPIDEMIA

Management of dyslipidemia in obesity requires a multifactorial approach that addresses both lipid abnormalities and underlying weight excess. Evidence-based guidelines recommend a stepwise strategy: lifestyle modification, pharmacotherapy, and, in selected cases, surgical interventions. [18, 19]

Lifestyle Modifications

a.      Dietary Interventions

Dietary modification is foundational in managing dyslipidemia and obesity:

Caloric Restriction: Reducing daily caloric intake by 500–750 kcal can induce gradual weight loss of 0.5–1 kg per week. [20]

Dietary Patterns:

Mediterranean Diet: High in monounsaturated fats, fruits, vegetables, whole grains, and fish; reduces LDL-C by ~10% and improves HDL-C. [21]

DASH Diet: Rich in fruits, vegetables, and low-fat dairy; lowers blood pressure and modestly reduces LDL-C. [22]

Macronutrient Focus: Reducing saturated fat (<7% of daily calories), trans fats, and refined carbohydrates while increasing fiber (20–30 g/day) improves triglycerides and HDL levels. [23]

Physical Activity

Structured exercise enhances lipid metabolism and insulin sensitivity:

Aerobic Exercise: ≥150 min/week of moderate-intensity activity reduces triglycerides by 20–30 mg/dL and increases HDL-C by 3–8 mg/dL. [24]

Resistance Training: Improves lean mass, reduces visceral fat, and supports long-term weight maintenance.

Combined Approach: Aerobic + resistance training is most effective for overall cardiometabolic risk reduction. [25]

Behavioral Interventions

Behavioral counseling, goal setting, self-monitoring, and motivational interviewing improve adherence to diet and exercise plans. Multidisciplinary programs have shown sustained weight loss of 5–10% over 12 months. [26]

Pharmacotherapy

Pharmacologic management targets lipid abnormalities and/or weight reduction, particularly for patients failing lifestyle measures. [2,4,12, 19, 20,21,27]

Lipid-Lowering Agents

Anti-Obesity Medications

·           Clinical note: Anti-obesity pharmacotherapy is indicated for BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities (dyslipidemia, T2DM, hypertension) .Combination therapy may be considered for refractory cases. [4,6,23, 24,27,14,21]

Surgical Interventions

Bariatric surgery is recommended for severe obesity (BMI ≥40 kg/m² or ≥35 kg/m² with comorbidities):

Procedures: Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding.

Effects on Dyslipidemia: LDL-C reduction 20–35%, TG reduction 30–50%, HDL-C increase 15–25%.[22-24]

Long-term Outcomes: Reduced incidence of ASCVD, diabetes remission and improved survival.[43]

Emerging Therapies

Inclisiran: siRNA targeting PCSK9; administered twice yearly; LDL-C reduction ~50%.[27]

Bempedoic acid + ezetimibe combination: Synergistic LDL-lowering effect, especially in statin-intolerant patients.[14]

New GLP-1/GIP agonists: Early trials show weight loss >20% with significant lipid improvements [6]

Personalized Approach

Management should be individualized considering:

ü  Baseline lipid profile

ü  Comorbidities (diabetes, NAFLD, CKD)

ü  Patient preferences and adherence potential

ü  Risk-benefit analysis of pharmacologic vs surgical interventions

CLINICAL FEATURES AND DIAGNOSIS

Clinical Presentation

Obesity-related dyslipidemia is often asymptomatic, discovered during routine screening.

Classic features may include:

Central/visceral obesity (waist circumference >102 cm men, >88 cm women in Western populations; lower cut-offs in Asian populations).[4]

Atherogenic dyslipidemia pattern on laboratory testing: elevated triglycerides, low HDL-C, normal or mildly elevated LDL-C, presence of small dense LDL.[21]

Associated comorbidities: hypertension, insulin resistance, type 2 diabetes, fatty liver.

Physical examination may reveal:

ü  Xanthelasma or tendon xanthomas (in familial forms)

ü  Acanthosis nigricans indicating insulin resistance

ü  Hepatomegaly in NAFLD

Diagnostic Evaluation

Laboratory Investigations:

Imaging Studies:

§  Ultrasound / FibroScan: Assess hepatic steatosis

§  Coronary artery calcium scoring: Evaluate subclinical atherosclerosis in high-risk patients

§  DXA / CT: Quantify visceral fat and body composition

Diagnostic Criteria for Metabolic Syndrome (any 3 of 5):

§  Waist circumference ≥102 cm (men), ≥88 cm (women)

§  TG ≥150 mg/dL

§  HDL-C <40 mg/dL (men), <50 mg/dL (women)

§  Blood pressure ≥130/85 mmHg

§  Fasting glucose ≥100 mg/dL.[22]

SPECIAL POPULATIONS AND MONITORING

Diabetes Mellitus

Patients with T2DM and obesity are at higher risk for atherogenic dyslipidemia, often requiring combination therapy (statin + ezetimibe/PCSK9 inhibitor) for LDL-C control. GLP-1 receptor agonists or SGLT2 inhibitors aid both weight reduction and cardiovascular risk mitigation.[23,24]

Chronic Kidney Disease

CKD modifies lipid metabolism; fibrates must be used cautiously due to risk of myopathy. Statins remain safe in early-stage CKD and reduce ASCVD events.[27]

Familial Hypercholesterolemia

Obese patients with FH require early intensive therapy. PCSK9 inhibitors and combination therapy may be indicated to achieve LDL-C targets.[14]

Elderly

Management must balance risk of polypharmacy, frailty and comorbidities. Lifestyle interventions are still beneficial, but aggressive pharmacotherapy should be individualized.[6]

Monitoring Strategies

Lipid profile: Every 4–12 weeks initially after therapy initiation, then every 3–12 months.

Liver and kidney function: Periodically if on statins, fibrates, or other lipid-lowering drugs.

Weight and waist circumference: Track monthly during lifestyle or pharmacologic intervention.

Cardiovascular imaging (optional): For high-risk patients to assess regression/progression of atherosclerosis.[4,21]

OUTCOMES AND LANDMARK TRIALS

Lipid-Lowering Trials

IMPROVE-IT: Statin + ezetimibe vs statin monotherapy; reduced LDL-C to 53 mg/dL and lowered major cardiovascular events.[20]

FOURIER: Evolocumab in high-risk ASCVD; LDL-C reduction 59%, 15% relative risk reduction in MACE.[14]

ODYSSEY OUTCOMES: Alirocumab in post-ACS patients; LDL-C reduction 62%, significant reduction in cardiovascular mortality.[2]

Weight-Loss Interventions

·      STEP trials: Semaglutide 2.4 mg weekly in obese adults; average weight loss 15–17%, improved TG (-20–25%) and LDL-C (-5–10%).[23,13]

·      Tirzepatide SURPASS studies: Dual GIP/GLP-1 agonist; weight loss up to 20%, triglycerides down 25–30%.[14]

·      Bariatric Surgery (SOS study): 10-year follow-up; significant reduction in ASCVD events and mortality, sustained LDL-C and TG improvement.[23,24]

Clinical Implications

Combined therapy (lifestyle + pharmacotherapy ± surgery) in obesity-related dyslipidemia improves:

1. Early Screening and Diagnosis:
Given the strong association between obesity and dyslipidemia, routine screening for lipid abnormalities should be conducted in individuals with a body mass index (BMI) ≥30 kg/m². Early detection allows for timely intervention and prevention of cardiovascular events.[26]

2. Lifestyle Modifications:
Weight loss through dietary changes and increased physical activity is the cornerstone of managing obesity-related dyslipidemia. Studies have shown that even a modest weight reduction can lead to significant improvements in lipid profiles.[22]

3. Pharmacotherapy:
In cases where lifestyle modifications are insufficient, pharmacological treatments may be necessary. Statins remain the first-line therapy for lowering LDL-C levels. However, for patients with elevated TG levels, fibrates or omega-3 fatty acids may be considered.

4. Monitoring and Follow-Up:
Regular monitoring of lipid levels is essential to assess the effectiveness of treatment strategies. Adjustments to therapy should be made based on lipid profiles and the presence of any side effects.[26]

5. Multidisciplinary Approach:
Management of obesity-related dyslipidemia should involve a team of healthcare providers, including primary care physicians, cardiologists, dietitians, and exercise specialists, to ensure comprehensive care.

6. Public Health Strategies:
Public health initiatives aimed at reducing obesity prevalence through education, access to healthy foods and promotion of physical activity can have a significant impact on reducing the incidence of dyslipidemia and subsequent cardiovascular diseases.[22]

FUTURE DIRECTIONS AND RESEARCH PRIORITIES

Novel lipid-lowering agents: Inclisiran, bempedoic acid combinations, ANGPTL3 inhibitors.

Next-generation anti-obesity drugs: Dual GIP/GLP-1 agonists, combination incretin therapies.

Precision medicine: Genetic and metabolic profiling to personalize therapy.

Digital health: Wearables and apps for real-time diet, exercise, and weight tracking.

Population-level interventions: Policy-driven approaches to reduce obesity and improve diet quality globally. [4,8,25,26]

CONCLUSION

Obesity-related dyslipidemia is a major contributor to global cardiovascular morbidity. Early recognition, comprehensive risk assessment, and multifactorial management combining lifestyle, pharmacotherapy, and surgery are critical. Recent advances in lipid-lowering and weight-loss medications, supported by landmark trials, offer new opportunities to reduce ASCVD risk and improve patient outcomes. A personalized, evidence-based approach, integrating monitoring and emerging therapies, is essential for effective long-term management.

REFERENCES

1.        Carey VJ, et al. Obesity, dyslipidemia, and cardiovascular disease. J Clin Lipidol. 2024;18:100–120.

2.        Zheng C, et al. Association between obesity and the prevalence of dyslipidemia among adults aged 35 and above in Ganzhou, China. Sci Rep. 2024;14(1):1–10.

3.        National Lipid Association. NLA Recommendations & Statements. National Lipid Association; 2024.

4.        Won H, et al. 2024 KSoLA Consensus on Secondary Dyslipidemia. J Lipid Atheroscler. 2024;13(2):123–145.

5.        Mohseni P, et al. The synergistic effect of obesity and dyslipidemia on hypertension. J Clin Hypertens. 2024;26(5):1–8.

6.        Bays HE, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association. J Clin Lipidol. 2024;18(3):e320–e350.

7.        American Association of Clinical Endocrinology. 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia. AACE; 2025.

8.        Gaita L, et al. Lipid disorders management strategies. J Clin Lipidol. 2024;18(1):1–10.

9.        Shekhawat VS, et al. Evaluation of the prevalence and pattern of dyslipidemia in newly diagnosed type 2 diabetes mellitus patients. J Med Sci Clin Res. 2024;12(5):1–10.

10.    Calapkulu M, et al. Prevalence of obesity and dyslipidemia in maturity onset diabetes of the young patients. Endocr Res Pract. 2025;29(1):9–14.

11.    American Diabetes Association. Cardiovascular disease and risk management: Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S179–S188.

12.    Lee H, et al. National trends in dyslipidemia prevalence, awareness, and treatment in the United States. Sci Rep. 2025;15(1):1–10.

13.    Formisano E, et al. The impact of overweight on lipid phenotype in different populations. Lipids Health Dis. 2024;23(1):1–10.

14.    Zeljkovic A, et al. Obesity and dyslipidemia in early life: Impact on cardiometabolic health. Metabolism. 2024;137:154–160.

15.    European Society of Cardiology. ESC Consensus Statement on Obesity and Cardiovascular Disease: Key points. Eur Heart J. 2024.

16.    Ruan H, et al. Dyslipidemia versus obesity as predictors of ischemic stroke outcomes. Lipids Health Dis. 2024;23(1):1–10.

17.    National Lipid Association. Practical Pearls: Dyslipidemia management in metabolic dysfunction-associated steatotic liver disease. National Lipid Association; 2024.

18.    Brunham LR, et al. Epidemiology, risk factors, and effect of lipid lowering in dyslipidemia. Can J Cardiol. 2024;40(8):1–10.

19.    Mach F, et al. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidemias. Atherosclerosis. 2025;292:1–10.

20.    Kittleson MM, et al. 2025 ACC Scientific Statement on the Management of Obesity in Heart Failure. J Am Coll Cardiol. 2025;85(5):456–478.

21.    Dakhal T, et al. Lipid dysregulation in diseases: Core concepts, targets, and therapeutic approaches. Lipids Health Dis. 2025;24(1):1–15.

22.    Gallo G, et al. Update on obesity and cardiovascular risk. Nutrients. 2024;16(16):2781.

23.    Okoh P, et al. An integrated pathophysiological and clinical perspective of the synergistic effects of obesity, hypertension, and hyperlipidemia on cardiovascular health: A systematic review. Cureus. 2024;16(10):e72443.

24.    Formisano E, et al. Decline in LDL-C control in patients with dyslipidemia and obesity. J Clin Lipidol. 2025;19(1):45–53.

25.    Pappan N. Dyslipidemia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

26.    Grundy SM. Guidelines for the management of high blood cholesterol. National Institutes of Health; 2022.

27.    Zhang M, et al. The impact of overweight on lipid phenotype in different populations. Lipids Health Dis. 2024;23(1):1–10